Common Blood Thinner Dabigatran Found to Reverse Bone Loss in Aging Models
Dabigatran, an FDA-approved anticoagulant, simultaneously boosts bone formation and suppresses bone resorption via dual molecular targets.
Summary
Researchers discovered that dabigatran, a widely prescribed blood-thinning drug, can also fight osteoporosis by acting on two separate molecular targets at once. In aging and ovariectomized mice, the drug preserved bone density and microstructure. In cell studies, it boosted the activity of bone-building cells while simultaneously suppressing bone-dissolving cells. The drug works by binding to PRKAB1, activating the AMPK pathway and promoting autophagy to enhance bone formation, and by binding to RELA to suppress the NF-κB inflammatory pathway and reduce bone breakdown. Because dabigatran is already FDA-approved and taken orally, this drug-repurposing strategy could fast-track a new treatment for osteoporosis, a major cause of fractures, disability, and reduced quality of life in older adults.
Detailed Summary
Osteoporosis is one of the most consequential age-related diseases, affecting millions of older adults and dramatically increasing the risk of fractures, loss of independence, and premature death. Current treatments either suppress bone resorption or promote bone formation, but rarely do both simultaneously. A new study published in Research identifies dabigatran — an oral anticoagulant already approved by the FDA for stroke prevention — as a potent dual-action candidate for restoring bone homeostasis.
The researchers conducted a phenotypic screen of an FDA-approved drug library, focusing on regulators of two central bone-remodeling pathways: RUNX2 (which drives bone formation) and NF-κB (which drives bone breakdown). Dabigatran emerged as a top hit capable of modulating both pathways. In mouse models mimicking postmenopausal and age-related osteoporosis, dabigatran administration significantly reduced bone loss and preserved trabecular bone microarchitecture.
Mechanistically, the study used limited proteolysis-coupled mass spectrometry to identify the precise molecular targets. In bone marrow mesenchymal stem cells, dabigatran binds to PRKAB1 (a regulatory subunit of AMPK) at alanine-77, activating AMPK, inhibiting mTORC1, enhancing autophagic flux, and ultimately promoting osteogenesis. Simultaneously, in osteoclast precursors, it binds RELA at arginine-50, suppressing NF-κB signaling and reducing osteoclast differentiation — making this a true single-molecule, dual-target pharmacological strategy.
For clinicians and longevity-focused practitioners, the implications are significant. Osteoporosis management in older adults often requires long-term polypharmacy with considerable side-effect burden. An existing, orally available, well-tolerated drug that simultaneously builds bone and reduces breakdown could represent a major therapeutic advance. The AMPK-autophagy axis activated here also overlaps with core longevity pathways studied in the context of aging biology more broadly.
Important caveats apply: this summary is based on the abstract only, with full methodology not reviewed. All efficacy data are preclinical (mouse models and cell culture). Clinical trials in humans will be necessary before any practice changes are justified. Anticoagulant risks would also need careful evaluation in an osteoporotic elderly population prone to bleeding.
Key Findings
- Dabigatran preserved bone density and microarchitecture in both aged and ovariectomized mouse osteoporosis models.
- The drug activated AMPK and autophagy in bone-forming stem cells by binding PRKAB1 at alanine-77.
- It simultaneously suppressed NF-κB signaling in osteoclast precursors by binding RELA at arginine-50.
- A single FDA-approved molecule was shown to both promote bone formation and inhibit bone resorption concurrently.
- AMPK-mTORC1-autophagy axis activation by dabigatran links this finding to established longevity signaling pathways.
Methodology
Researchers screened an FDA-approved drug library using phenotypic assays targeting RUNX2 and NF-κB bone-remodeling pathways. In vivo validation used ovariectomized and aged mouse models; in vitro studies used bone marrow-derived macrophages and mesenchymal stem cells. Molecular targets were identified using limited proteolysis-coupled mass spectrometry.
Study Limitations
This summary is based on the abstract only; full methodology and data were not reviewed. All findings are preclinical (mouse models and cell culture); human efficacy and safety in the osteoporotic elderly population have not been established. Anticoagulant risks in a fracture-prone, elderly demographic would require careful clinical evaluation in future trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: